Crossmark Global Holdings Inc. Grows Stock Holdings in Haleon plc (NYSE:HLN)

Crossmark Global Holdings Inc. increased its stake in Haleon plc (NYSE:HLNFree Report) by 1.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 282,602 shares of the company’s stock after buying an additional 4,270 shares during the period. Crossmark Global Holdings Inc.’s holdings in Haleon were worth $2,326,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HLN. FMR LLC increased its stake in Haleon by 22.2% during the 3rd quarter. FMR LLC now owns 53,951,936 shares of the company’s stock valued at $449,420,000 after purchasing an additional 9,812,040 shares in the last quarter. Wellington Management Group LLP purchased a new position in Haleon in the 3rd quarter worth approximately $42,640,000. Envestnet Asset Management Inc. lifted its position in Haleon by 121.2% in the 3rd quarter. Envestnet Asset Management Inc. now owns 5,931,187 shares of the company’s stock valued at $49,407,000 after acquiring an additional 3,249,517 shares in the last quarter. Cambiar Investors LLC purchased a new stake in Haleon during the 4th quarter valued at $15,225,000. Finally, Kayne Anderson Rudnick Investment Management LLC increased its holdings in shares of Haleon by 6,593.0% in the 3rd quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,692,937 shares of the company’s stock worth $14,102,000 after purchasing an additional 1,667,643 shares in the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on HLN. HSBC assumed coverage on Haleon in a report on Wednesday, April 17th. They issued a “buy” rating for the company. Berenberg Bank initiated coverage on shares of Haleon in a report on Wednesday. They issued a “buy” rating on the stock. Finally, Argus reiterated a “buy” rating on shares of Haleon in a research note on Tuesday, March 26th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Haleon has an average rating of “Moderate Buy”.

View Our Latest Analysis on HLN

Haleon Trading Down 0.7 %

Haleon stock opened at $8.52 on Friday. Haleon plc has a 52-week low of $7.70 and a 52-week high of $8.96. The company has a market cap of $38.90 billion, a P/E ratio of 28.40, a P/E/G ratio of 2.28 and a beta of 0.26. The company has a quick ratio of 0.73, a current ratio of 1.04 and a debt-to-equity ratio of 0.53. The business has a 50-day simple moving average of $8.33 and a two-hundred day simple moving average of $8.34.

Haleon (NYSE:HLNGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of $0.11 by $0.01. Haleon had a net margin of 9.68% and a return on equity of 13.17%. The business had revenue of $3.70 billion for the quarter, compared to the consensus estimate of $3.71 billion. Analysts predict that Haleon plc will post 0.46 EPS for the current year.

About Haleon

(Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Recommended Stories

Want to see what other hedge funds are holding HLN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haleon plc (NYSE:HLNFree Report).

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.